DATE: December 6, 2018
TIME: 6:00am PST, 9:00am EST, 3:00pm CET
Alterations in the bone and mineral metabolism is of great concern in patients with chronic kidney disease (CKD). As the glomerular filtration rate (GFR) decreases, phosphatemia tends to increase while the renal secretion of the active vitamin D metabolite decreases with, consequently, increases in both serum PTH and FGF23 levels. This the pathophysiological basis of the so-called CKD-bone and mineral disorders (MBD). Experts in Nephrology have published international guidelines, called the KDIGO/CKD-MBD, to help the colleagues to deal with these disorders. In this webinar, the KDIGO recommendations concerning the measurement of the serum concentration of PTH, vitamin D metabolites and FGF23 will be discussed.
Understand the bone metabolic disorder in CKD patients
Which is the mechanism that regulate the calcium and phosphorus absorption in patient with altered hormone activities
Know the utility of a few fundamental markers to decide the CKD patient management